DNA IL-12: Phase II started

OncoSec began an open-label, U.S. Phase II trial to evaluate intratumorally injected DNA IL-12 followed by in vivo electroporation using OncoSec's OMS ElectroImmunotherapy technology on days 1, 5 and ...